
BioCardia Inc. (BCDA) Stock Forecast & Price Target
BioCardia Inc. (BCDA) Analyst Ratings
Bulls say
BioCardia is fully committed to advancing its cell therapy platforms, with a focus on treating heart failure and respiratory diseases, and has received support from the FDA and positive initial trial results. The company plans to continue enrollment in its Phase 3 trials and submit for market approval in Japan, with promising results in a recent study. However, there are potential risks and obstacles that could impact their projected price target.
Bears say
BioCardia is a clinical-stage company with two cell therapy platforms in development for cardiovascular and pulmonary diseases. While their CardiAMP platform has shown potential for treating ischemic heart failure and refractory angina, their allogeneic mesenchymal stem cell therapy platform is still in the early stages of clinical trials. Additionally, the company's financials show a negative net income of $6.87 million in the latest quarter and a low cash balance of $2.34 million. Overall, this coupled with their minimal revenue and high operating expenses suggests a high level of risk and uncertainty for investors.
This aggregate rating is based on analysts' research of BioCardia Inc. and is not a guaranteed prediction by Public.com or investment advice.
BioCardia Inc. (BCDA) Analyst Forecast & Price Prediction
Start investing in BioCardia Inc. (BCDA)
Order type
Buy in
Order amount
Est. shares
0 shares